Regulus Therapeutics Inc ( (RGLS) ) has released its Q1 earnings. Here is a breakdown of the information Regulus Therapeutics Inc presented to its investors.
Regulus Therapeutics Inc., a biopharmaceutical company based in San Diego, focuses on the discovery and development of innovative medicines targeting microRNAs, with a strong emphasis on treating autosomal dominant polycystic kidney disease (ADPKD).
In the first quarter of 2025, Regulus Therapeutics announced significant developments, including an agreement to be acquired by Novartis for a total equity value of up to $1.7 billion. The company also reported positive topline data from its Phase 1b study of farabursen, a treatment for ADPKD, and is preparing to initiate a Phase 3 trial later this year.
Financially, Regulus reported a net loss of $9.6 million for the first quarter, with research and development expenses rising to $6.8 million. Despite the loss, the company maintains a cash runway extending into early 2026, with $65.4 million in cash, cash equivalents, and short-term investments as of March 31, 2025.
Strategically, the acquisition by Novartis is expected to enhance the development and commercialization of farabursen, potentially bringing new treatment options to patients with ADPKD. The transaction is anticipated to close in the second half of 2025, pending regulatory approvals and customary closing conditions.
Looking ahead, Regulus remains focused on advancing its clinical pipeline, with the upcoming Phase 3 trial of farabursen poised as a critical step towards achieving regulatory milestones and potential accelerated approval pathways.